293207
Pain medication use by participants in a yoga dosing study for chronic low back pain
Methods: The Yoga Dosing Study was a 12-week RCT comparing once- vs. twice-weekly standardized 75-minute hatha yoga classes for 95 adults with nonspecific cLBP. Recruitment and classes occurred at a large safety-net hospital and five affiliated community health centers. Primary outcomes measured at 12 weeks were average back pain intensity in the previous week (0-10), back-related function (Roland-Morris Disability Questionnaire), and pain medication use (yes/no) during the previous week. We collected data on pain medication use, dosage and type (NSAID, opiate, acetaminophen, or other) during baseline, 6, and 12 week surveys.
Results: No statistically significant differences in overall pain medication use were found between the two groups at baseline (1x/wk= 71%, 2x/wk=74%). After 6 weeks, pain medication use decreased in both the once- and twice-weekly groups by 27% and 35%, respectively. There was a significant decrease in NSAID use in both groups. Opiate use decreased in both groups, but it was not significant. There was no significant difference in overall medication use between the 6 and 12 week survey dates.
Conclusions: Pain medication use decreased similarly in participants engaged in once- or twice-weekly yoga classes. Further analyses of specific doses used will be performed and presented.
Learning Areas:
Chronic disease management and preventionLearning Objectives:
Describe the literature on Yoga for Chronic Low Back Pain and prescription use for chronic pain management.
Assess the pain medicine results of a Yoga Dosing Study comparing once per week to twice per week yoga classes for chronic low back pain.
Identify the benefits of yoga once- or twice-weekly on pain medication usage.
Keyword(s): Adult Health, Alternative Medicine/Therapies
Qualified on the content I am responsible for because: I am the presenter and assisted in preparing the manuscript
Any relevant financial relationships? No
I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.